Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester M20 4BX, UK
MetadataShow full item record
AbstractBreast cancer remains a leading cause of death worldwide. Our increased understanding of cellular mechanisms inherent to cancer has led to the development of new therapeutic targets. One such therapy is that of poly(ADP-ribose) polymerase (PARP) inhibitors, with PARP playing a key role in the repair of single stranded DNA breaks. The development of drugs able to inhibit PARP led to their investigation in tumors that have defective DNA repair, including that of BRCA1/2-associated cancers. The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutatioN This article will review the findings and potential implications of the trial.
CitationArmstrong AC, Clay V. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. Future Oncol. 2019;15(20):2327-35.
- Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
- Authors: Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J, Collaborating Investigators
- Issue date: 2021 Jul
- Olaparib for the treatment of breast cancer.
- Authors: Griguolo G, Dieci MV, Guarneri V, Conte P
- Issue date: 2018 Jun
- Olaparib Keeps Hereditary Breast Tumors in Check.
- Issue date: 2017 Aug
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
- Authors: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P
- Issue date: 2017 Aug 10
- BRCA1/2 testing: therapeutic implications for breast cancer management.
- Authors: Tung NM, Garber JE
- Issue date: 2018 Jul